公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria | Huang, Chian Tzu; Chu, Yu Long; TUNG-HUNG SU ; SHANG-CHIN HUANG ; TAI-CHUNG TSENG ; SHIH-JER HSU ; SIH-HAN LIAO ; CHUN-MING HONG ; CHEN-HUA LIU ; HUNG-CHIH YANG ; CHUN-JEN LIU ; PEI-JER CHEN ; JIA-HORNG KAO | Liver Cancer | | | |
2002 | Osteonecrosis of the femoral head in a human immunodeficiency virus type 1-infected patient with lipodystrophy | YU-CHIEH TSAI ; CHEN-HUA LIU ; Liao C.-H.; Chen M.-Y.; CHIEN-CHING HUNG | Journal of the Formosan Medical Association | 4 | 5 | |
2022 | Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 | CHEN-HUA LIU ; JIA-HORNG KAO | Hepatology International | 7 | 8 | |
2019 | Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis | CHEN-HUA LIU ; Shih Y.-L; Yang S.-S; Lin C.-L; YU-JEN FANG ; Cheng P.-N; Chen C.-Y; Peng C.-Y; Hsieh T.-Y; Chiu Y.-C; TUNG-HUNG SU ; CHUN-JEN LIU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 7 | 7 | |
2007 | Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV [6] | CHEN-HUA LIU ; DING-SHINN CHEN ; JIA-HORNG KAO | New England Journal of Medicine | 1 | 1 | |
2009 | Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses | CHUN-JEN LIU ; Chuang W.; Lee C.; Yu M.; Lu S.; Wu S.; Liao L.; CHI-LING CHEN ; Kuo H.; Chao Y.; Tung S.; Yang S.; JIA-HORNG KAO ; CHEN-HUA LIU ; Su W.; Lin C.; YUNG-MING JENG ; PEI-JER CHEN ; DING-SHINN CHEN | Gastroenterology | 182 | 157 | |
2015 | Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial | CHEN-HUA LIU ; Huang, Chung-Feng; CHUN-JEN LIU ; Dai, Chia-Yen; Huang, Jee-Fu; JOU-WEI LIN ; Liang, Cheng-Chao; Yang, Sheng-Shun; CHIH-HUNG LIN ; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang, Wan-Long; JIA-HORNG KAO ; Yu, Ming-Lung | Scientific reports | 8 | 8 | |
2015 | Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial | CHEN-HUA LIU ; CHUN-JEN LIU ; Huang C.-F; JOU-WEI LIN ; Dai C.-Y; Liang C.-C; Huang J.-F; Hung P.-H; Tsai H.-B; MENG-KUN TSAI ; CHIH-YUAN LEE ; Chen S.-I; Yang S.-S; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang W.-L; Yu M.-L; JIA-HORNG KAO | Gut | 36 | 30 | |
2015 | Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study | CHEN-HUA LIU ; WANG-HUEI SHENG ; HSIN-YUN SUN ; SZU-MIN HSIEH ; Lo Y.-C; CHUN-JEN LIU ; TUNG-HUNG SU ; HUNG-CHIH YANG ; Liu W.-C; PEI-JER CHEN ; DING-SHINN CHEN ; CHIEN-CHING HUNG ; JIA-HORNG KAO | Scientific Reports | 13 | 12 | |
2015 | Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | CHEN-HUA LIU ; Huang, Chung-Feng; CHUN-JEN LIU ; Dai, Chia-Yen; Huang, Jee-Fu; JOU-WEI LIN ; Liang, Cheng-Chao; Yang, Sheng-Shun; Lin, Chih-Lin; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang, Wan-Long; JIA-HORNG KAO ; Yu, Ming-Lung | Scientific reports | 7 | 7 | |
2010 | Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; JOU-WEI LIN ; Chen S.-I.; Hung P.-H.; Tsai H.-B.; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Clinical Infectious Diseases | 30 | 26 | |
2009 | Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; Tsai H.-B.; Hung P.-H.; SHIH-JER HSU ; Chen S.-L.; JOU-WEI LIN ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gut | 26 | 23 | |
2008 | Pegylated interferon α-2a versus standard interferon α-2a for treatment-naïve dialysis patients with chronic hepatitis C: A randomised study | CHEN-HUA LIU ; Liang C.-C.; JOU-WEI LIN ; Chen S.-I.; Tsai H.-B.; Chang C.-S.; Hung P.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN | Gut | 67 | 61 | |
2008 | Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial | CHEN-HUA LIU ; CHUN-JEN LIU ; Lin C.-L.; Liang C.-C.; SHIH-JER HSU ; Yang S.-S.; Hsu C.-S.; TAI-CHUNG TSENG ; Wang C.-C.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Clinical Infectious Diseases | 183 | 170 | |
2013 | Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial | CHEN-HUA LIU ; Huang, Chung-Feng; CHUN-JEN LIU ; Dai, Chia-Yen; Liang, Cheng-Chao; Huang, Jee-Fu; Hung, Peir-Haur; HUNG-BIN TSAI ; MENG-KUN TSAI ; Chen, Shih-I; JOU-WEI LIN ; Yang, Sheng-Shun; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang, Wan-Long; Yu, Ming-Lung; JIA-HORNG KAO | Annals of internal medicine | 85 | 77 | |
2023 | Pre-operative gamma-glutamyl transferase levels predict outcomes in hepatitis B-related hepatocellular carcinoma after curative resection | TUNG-HUNG SU ; SHANG-CHIN HUANG ; CHI-LING CHEN ; SHIH-JER HSU ; SIH-HAN LIAO ; CHUN-MING HONG ; TAI-CHUNG TSENG ; CHEN-HUA LIU ; HUNG-CHIH YANG ; YAO-MING WU ; CHUN-JEN LIU ; PEI-JER CHEN ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 2 | 0 | |
2016 | Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C | Mah Y.-H.; CHEN-HUA LIU ; CHI-LING CHEN ; TAI-CHUNG TSENG ; CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 6 | 7 | |
2019 | Profile and value of FIB-4 in patients with dual chronic hepatitis C and B | CHUN-JEN LIU ; TAI-CHUNG TSENG ; Yang W.-T; TUNG-HUNG SU ; HUNG-CHIH YANG ; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 10 | 9 | |
2013 | Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype | Huang C.-F.; Yu M.-L.; JIA-HORNG KAO ; TAI-CHUNG TSENG ; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; CHEN-HUA LIU | Journal of Clinical Virology | 16 | 17 | |
2022 | Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma | Wang, Sung-Yin; TUNG-HUNG SU ; BANG-BIN CHEN ; CHUN-JEN LIU ; CHEN-HUA LIU ; HUNG-CHIH YANG ; TAI-CHUNG TSENG ; PEI-JER CHEN ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 4 | 4 | |